Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 7/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RHEB | Q15382 | 1/20 | 0.36 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1482801 | 0.90 | TBXA2R (0.44) | TBXA2RDRD2KDM4EKMT2ANR1H4 | |
| SCHEMBL1482913 | 0.90 | KDM4E (0.48) | TBXA2RDRD2KDM4EKMT2ASOS1 | |
| SCHEMBL1482209 | 0.89 | LPAR2 (0.42) | TBXA2RDRD2KDM4ENR1H4HTT | |
| SCHEMBL1483096 | 0.88 | DRD2 (0.55) | TBXA2RDRD2MAPTDCTPP1GAA | |
| SCHEMBL1482644 | 0.84 | NR1H4 (0.43) | TBXA2RDRD2NR1H4 | |
| SCHEMBL1482490 | 0.83 | DRD2 (0.49) | TBXA2RDRD2KMT2AMAPT | |
| SCHEMBL1482410 | 0.82 | KMT2A (0.52) | KDM4EKMT2AMAPTHTTSMN1; SMN2 | |
| SCHEMBL1482695 | 0.82 | MCHR1 (0.39) | KDM4ENR1H4MAPT | |
| SCHEMBL1482665 | 0.81 | KDM4E (0.47) | TBXA2RDRD2KDM4EKMT2ANR1H4 | |
| SCHEMBL1482341 | 0.80 | KMT2A (0.47) | KMT2ASOS1MAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | TBXA2R 92/4885DRD2 1464/4885KDM4E 1791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.